硼替佐米用于轻链沉积病的诱导治疗：血液学反应迅速但肾脏病变持续存在。 - Suppr

Suppr

超能文献

Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.

作者信息

Minarik Jiri, Scudla Vlastimil, Tichy Tomas, Pika Tomas, Bacovsky Jaroslav, Lochman Pavel, Zadrazil Josef

出版信息

Leuk Lymphoma. 2012 Feb;53(2):330-1. doi: 10.3109/10428194.2011.619610. Epub 2011 Oct 24.

DOI:10.3109/10428194.2011.619610

PMID:21883030

Abstract

摘要

相似文献

Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.

Leuk Lymphoma. 2012 Feb;53(2):330-1. doi: 10.3109/10428194.2011.619610. Epub 2011 Oct 24.

Managing light chain deposition disease.

Leuk Lymphoma. 2012 Feb;53(2):183-4. doi: 10.3109/10428194.2011.622423. Epub 2011 Dec 5.

Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.

Ann Hematol. 2010 Aug;89(8):821-2. doi: 10.1007/s00277-009-0867-7. Epub 2009 Dec 2.

Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.

Leuk Lymphoma. 2013 Jun;54(6):1324-6. doi: 10.3109/10428194.2012.738816. Epub 2012 Nov 15.

Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.

Med Oncol. 2012 Jun;29(2):1197-201. doi: 10.1007/s12032-011-9938-4. Epub 2011 Apr 9.

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.

Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035.

Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.

J Hematol Oncol. 2009 Apr 28;2:19. doi: 10.1186/1756-8722-2-19.

Successful bone reconstruction after bortezomib therapy in a myeloma patient.

Int J Hematol. 2011 Sep;94(3):221. doi: 10.1007/s12185-011-0913-9. Epub 2011 Aug 23.

Diagnosis and the current trends in multiple myeloma therapy.

Pol Arch Med Wewn. 2008 Oct;118(10):563-6.

Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.

BMJ Case Rep. 2012 Dec 20;2012:bcr2012007646. doi: 10.1136/bcr-2012-007646.

引用本文的文献

Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature.

Front Oncol. 2025 Jan 30;15:1466323. doi: 10.3389/fonc.2025.1466323. eCollection 2025.

Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies.

Ann Hematol. 2025 Apr;104(4):2083-2093. doi: 10.1007/s00277-024-05911-9. Epub 2024 Aug 28.

Dyspnea and cough in a 68-year-old female with light chain deposition disease.

Respir Med Case Rep. 2023 Mar 20;43:101839. doi: 10.1016/j.rmcr.2023.101839. eCollection 2023.

Treatment of Light Chain Deposition Disease: A Systematic Review.

J Hematol. 2022 Aug;11(4):123-130. doi: 10.14740/jh1038. Epub 2022 Aug 30.

Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone.

Ren Fail. 2021 Dec;43(1):1425-1427. doi: 10.1080/0886022X.2021.1988967.

[Clinical features and prognosis of patients with primary light chain deposition disease].

Zhonghua Xue Ye Xue Za Zhi. 2017 Mar 14;38(3):253-256. doi: 10.3760/cma.j.issn.0253-2727.2017.03.017.

Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male.

Case Rep Nephrol. 2016;2016:7485695. doi: 10.1155/2016/7485695. Epub 2016 Dec 19.

Portal hypertension related to light chain deposition disease of liver: an enlightening experience.

BMJ Case Rep. 2013 May 29;2013:bcr2013009553. doi: 10.1136/bcr-2013-009553.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验